Journal article

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours

Sally M Hunter, Genevieve V Dall, Maria A Doyle, Richard Lupat, Jason Li, Prue Allan, Simone M Rowley, David Bowtell, Ian G Campbell, Kylie L Gorringe

BMC Research Notes | SPRINGERNATURE | Published : 2020

Abstract

OBJECTIVE: Ovarian fibromas and adenofibromas are rare ovarian tumours. They are benign tumours composed of spindle-like stromal cells (pure fibroma) or a mixture of fibroblast and epithelial components (adenofibroma). We have previously shown that 40% of benign serous ovarian tumours are likely primary fibromas due to the neoplastic alterations being restricted to the stromal compartment of these tumours. We further explore this finding by comparing benign serous tumours to pure fibromas. RESULTS: Performing copy number aberration (CNA) analysis on the stromal component of 45 benign serous tumours and 8 pure fibromas, we have again shown that trisomy of chromosome 12 is the most common aber..

View full abstract

Grants

Awarded by National Health & Medical Research Council of Australia (NHMRC)


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by Cancer Foundation of Western Australia


Awarded by National Health and Medical Research Council of Australia (NHMRC)


Funding Acknowledgements

This study was supported by the Victorian Breast Cancer Research Consortium (VBCRC) and the National Health & Medical Research Council of Australia (NHMRC, ID 628630) and the Emer Casey Foundation. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID400413 and ID400281). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation.